Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy in Relapsed Germ Cell Tumors (IT-94)
NCT00002566Phase 3Completed
- Sponsor
- Unicancer
- Start
- Feb 1994
- Primary completion
- Dec 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, etoposide and cyclophosphamide in Testicular Germ Cell Tumor (TGCT) and extragonadal germ cell tumor (EGGCT) (2 arms), sponsored by Unicancer. Primary endpoint: Event-Free Survival. Started Feb 1994; status: completed.
02
Drugs
carboplatinetoposidecyclophosphamide
03
Conditions
Testicular Germ Cell Tumor (TGCT)extragonadal germ cell tumor (EGGCT)
Beyond the preview
Go deeper on NCT00002566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002566.